A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
Clinical trial NCT05347225 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05347225
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-09
- Primary completion
- 2027-04-30
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.